Famotidine 20 MG for Pulmonary Arterial Hypertension

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Pulmonary Arterial Hypertension+6 MoreFamotidine 20 MG - Drug
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the drug famotidine is safe and effective in treating pulmonary arterial hypertension.

Eligible Conditions
  • Pulmonary Arterial Hypertension
  • Right-sided Heart Failure

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 0 to 24 weeks

0 to 24 weeks
Frequency of escalation for PAH focused care (increased diuretics, escalating doses of pulmonary vasodilators, and/or adding additional pulmonary vasodilators)
Health related quality of life (emPHasis-10 questionnaire)
New York Heart Association (NYHA) functional class
Right ventricular function by echocardiogram
Six-minute walk distance
nt-pro-BNP

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Famotidine
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

80 Total Participants · 2 Treatment Groups

Primary Treatment: Famotidine 20 MG · Has Placebo Group · Phase 2

Famotidine
Drug
Experimental Group · 1 Intervention: Famotidine 20 MG · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Famotidine
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 0 to 24 weeks

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,597 Previous Clinical Trials
1,569,069 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,593 Previous Clinical Trials
46,945,766 Total Patients Enrolled
20 Trials studying Pulmonary Arterial Hypertension
2,204 Patients Enrolled for Pulmonary Arterial Hypertension
Peter J Leary, MD, PhDPrincipal InvestigatorUniversity of Washington

Eligibility Criteria

Age 18 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
in a patient with a diagnosis of Eisenmenger syndrome Within five years, a right heart catheterization demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg, occlusion pressure of ≤ 15 mmHg, and pulmonary vascular resistance of ≥ 3 wood units can diagnose Eisenmenger syndrome in a patient.
People who have had a right heart catheterization in the last five years and have a mean pulmonary arterial pressure of at least 25 mmHg and an occlusion pressure of 15-20 mmHg will be considered for this study if their pulmonary vascular resistance is at least 9 wood units and they are being treated with a medication specific to pulmonary hypertension.
The text states that the person can walk a distance of 50 meters on their own.
, any race This is an announcement for anyone who is male or female and is between the ages of 18 and 80
WHO Group 1 Pulmonary Arterial Hypertension is a rare, life-threatening disorder in which the pressure in the pulmonary arteries is abnormally high
did not appear to alter the primary endpoint in the Phase 3 INOVA trial The study found that there was no significant difference in the primary endpoint between the group who received a stable dose of pulmonary vasodilators for 30 days prior to randomization and the group who did not.

Who else is applying?

What state do they live in?
Washington100.0%
What site did they apply to?
University of Washington Medical Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
3+100.0%
References